NCT01309828View on ClinicalTrials.gov

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

153

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Safety
Interventions
DRUG

Azilsartan medoxomil and chlorthalidone

Fixed-dose combination tablets.

DRUG

Olmesartan medoxomil and hydrochlorothiazide

Fixed-dose combination tablets.

Trial Locations (53)

Unknown

Kazanlak

Pleven

Sevlievo

Sofia

Varna

Mannheim

Nuremberg

Hamburg

Frankfurt am Main

Offenbach

Rodgau Dudenhofen

Essen

Goch

Wuppertal

Berlin

Daugavpils

Kuldīga

Limbaži

Riga

Tukums

Ventspils

Alytus

Kaunas

Klaipėda

Šiauliai

Vilnius

Amsterdam

Groningen

Maastricht

Venlo

Grodzisk Mazowiecki

Lodz

Torun

Warsaw

Zgierz

Banská Bystrica

Bardejov

Bratislava

Komárno

Košice

Martin

Nitra

Ružomberok

Svidník

Donetsk

Ivano-Frankivsk

Kharkiv

Kiev

Kyiv

Lutsk

Lviv

Vinnitsya

Vinnytsia

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT01309828 - Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease | Biotech Hunter | Biotech Hunter